1RV Stock Overview A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Rhythm Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Rhythm Pharmaceuticals Historical stock prices Current Share Price US$56.00 52 Week High US$62.50 52 Week Low US$32.20 Beta 2.15 1 Month Change -2.61% 3 Month Change 25.56% 1 Year Change 47.37% 3 Year Change 578.79% 5 Year Change 191.67% Change since IPO 158.22%
Recent News & Updates
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05 See more updates
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05
Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 23
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old Aug 26
Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023) Aug 07
Forecast to breakeven in 2026 Aug 07
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old Jul 31 Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer Jul 08
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index Jul 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome Jun 29
New minor risk - Profitability May 09
No longer forecast to breakeven May 08
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 08
First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023) May 07
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology Apr 30
Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 26
New major risk - Financial position Apr 04
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 03 Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 02
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist Mar 27 Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals Mar 21
Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022) Feb 23
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan Feb 23
New minor risk - Profitability Feb 09
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Feb 07
Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 01
New major risk - Share price stability Jan 23
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022) Nov 09
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) Nov 03
Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome Sep 07
Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022) Aug 02
Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 18
Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 Jun 19
Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients May 09
First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021) Mar 02
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome Jan 24
Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Nov 22
Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021) Nov 09
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology Nov 09
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023 Nov 03
Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA Nov 02
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development Oct 07
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022 Sep 20
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide) Sep 07
Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021) Aug 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome Jul 23
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France Jul 21
NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency Jul 19
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity Jul 13
Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment Jun 23
Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome Jun 17
Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022 Jun 14
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting May 04
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity Apr 07
Forecast to breakeven in 2024 Feb 26
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome Feb 25 Rhythm Pharmaceuticals, Inc. Announces Executive Promotions
Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS) Feb 17 Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder
High number of new directors Nov 04
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain Sep 23
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes Sep 21
Chief Medical Officer Murray Stewart has left the company Sep 15
Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Sep 10
Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity Aug 05
Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE Jul 25 Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index
Independent Director Todd Foley has left the company Jun 15
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency May 22
Chief Human Resources Officer has left the company May 01
Chairman recently bought €172k worth of stock Apr 01
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss At Up to Nine Months in Patients with Het Obesity on Setmelanotide At Endo 2021 Mar 21
Rhythm Pharmaceuticals, Inc. Announces Board Changes Mar 17
New 90-day low: €20.80 Mar 06
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities Jan 29
New 90-day high: €31.20 Jan 23
New 90-day high: €26.80 Jan 07
Rhythm Pharmaceuticals, Inc. Announces Committee Appointments Jan 05 Shareholder Returns 1RV DE Biotechs DE Market 7D 3.7% 4.0% 0.7% 1Y 47.4% -10.2% 8.4%
See full shareholder returns
Return vs Market: 1RV exceeded the German Market which returned 8.4% over the past year.
Price Volatility Is 1RV's price volatile compared to industry and market? 1RV volatility 1RV Average Weekly Movement 8.0% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1RV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
Show more Rhythm Pharmaceuticals, Inc. Fundamentals Summary How do Rhythm Pharmaceuticals's earnings and revenue compare to its market cap? 1RV fundamental statistics Market cap €3.35b Earnings (TTM ) -€254.88m Revenue (TTM ) €109.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1RV income statement (TTM ) Revenue US$112.53m Cost of Revenue US$12.81m Gross Profit US$99.72m Other Expenses US$361.29m Earnings -US$261.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.26 Gross Margin 88.61% Net Profit Margin -232.45% Debt/Equity Ratio 71.5%
How did 1RV perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 17:03 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Rhythm Pharmaceuticals, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Whitney Ijem Canaccord Genuity Corinne Johnson Goldman Sachs
Show 15 more analysts 
